Please Wait...

Medical Imaging

Biomarkers and Personalized Medicine: Essential Tools

  • 0
  • 28 Mar

The use of biomarkers is expanding across all stages in the drug development process, helping bring about new and innovative practices in the treatment of many diseases, including Alzheimer's and cancer. With their ability to revolutionize development of advanced therapeutics, biomarkers have become essential tools.

Read More

Pathway to Quality Cardiovascular Imaging Trials

  • 0
  • 13 Mar

Cardiovascular diseases are the leading cause of death in the world and as such, the cause, prevention and treatment of all cardiovascular disease remains a very active field in the research community. Cardiovascular Imaging is a primary therapeutic service area for Bioclinica, offering comprehensive centralized medical imaging services and support for the majority of all cardiovascular imaging (CVI) modalities leveraged to provide critical endpoint assessments in clinical research.

Read More

Trends in Asia Drug Development Market

  • 0
  • 01 Nov

Innovation and Harmonization on the Rise

As R&D costs continue to hit new heights and domestic participation in clinical trials wane, more and more biopharmaceutical companies are seeking ways to mitigate costs and access new patient populations. Over the past decade, these driving market forces have contributed to a sharp rise in R&D activities, pharmaceutical market size, and the number of clinical trials conducted in Asia.

Read More

The Art of the Rescue - Navigating Potential Pitfalls during Imaging Vendor Transition

  • 0
  • 21 Jul

Once considered a rarity within the medical imaging vendor space, the decision by sponsors to transition imaging core lab after startup has become increasingly more common. Due to the complexity of clinical trials, there may come a time where as a Sponsor you will need to transition vendors after study startup. Reasons for this change of service provider can typically involve challenges with the current provider's timelines, quality, resources, or expertise.

Read More
Bioclinica on Worldwide Business with Kathy Ireland

Worldwide Business with Kathy Ireland features Bioclinica!

  • 0
  • 06 May

Catch a candid discussion with Bioclinica experts as they discuss clinical trials and ways to simplify the clinical development process in a recent episode of Worldwide Business with Kathy Ireland®!

Each week the Fox Business Network sponsored program explores the real-world insights of corporate executives from around the globe.

Read More

Seeking Clarity in the Audit Approach

  • 0
  • 18 Apr

Many questions still remain several years after the July 2012 ODAC (Oncologic Drug Advisory Committee) Meeting on the "Evaluation of Radiologic Review of Progression-free Survival in Non-Hematologic Malignancies." Further investigation was recommended into the utility of taking an audit approach (central reads of a test sample) to identify potential bias in the local evaluation (LE) of patient data.

Read More
2015 Asia Events

Expanding Opportunities for Drug Development in Asia

  • 0
  • 06 Oct

Over the last decade, R&D activities, pharmaceutical market size, and the number of clinical trials in Asia has grown tremendously.  As a result, Asian biopharmaceutical companies are developing more products for commercialization in the global market, and International drug development service companies have moved many R&D functions and commercial operations to the APAC region.

Read More
Imaging biomarkers, molecular imaging in oncology clinical trials

Leveraging Imaging Biomarkers to Improve Drug Development

  • 0
  • 02 Jun

Clinicians need ways to better predict patient responses

The estimated cost for developing a drug is approaching upwards of $5 Billion dollars with a process spanning well over a decade. Coupled with high failure rates in late phase clinical trials and increased complexities in acquiring and analyzing clinical trial data, traditional approaches based on the premise of "one size fits all" are becoming less cost effective and suboptimal.

Read More

New Approaches for Measuring Muscle Fatty Infiltration

  • 0
  • 17 Apr

Clinical Trial FIT-ness: New Approaches for Measuring Fat

The presence of fatty infiltration in muscles of the lower extremities (thigh and calf) serves as a proxy for impaired muscle function and metabolic status, often seen with musculoskeletal diseases like osteoarthritis (OA), Sarcopenia, Duchenne Muscular Dystrophy, Pompe disease and Polymyositis/Dermatomyositis. Most clinical research for musculoskeletal diseases relies on non-invasive imaging methodologies for assessing changes in inter-muscular adipose tissue (inter-MAT), intra-muscular adipose tissue (intra-MAT) and muscle in the lower extremities.

Read More

Evaluating Cardiotoxicity: The Importance of Strain Imaging

  • 0
  • 27 Feb

Cardiotoxicity stemming from oncology drugs is a common problem facing drug sponsors, clinicians and cancer patients. Drug-induced cardiotoxic effects can be classified based on the mechanism of toxicity into three broad categories: myocardial damage and Left Ventricular (LV) dysfunction, vascular abnormalities and hypertension, and QT prolongation and arrhythmias.

Read More

Escalating Role of Medical Imaging in AD Clinical Trials

  • 0
  • 30 Jan

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. Disease modifying therapies are desperately needed and many potential treatments are currently being tested in clinical trials. The role and impact of medical imaging in AD trials continues to grow, especially as clinicians and scientists seek to define and treat AD at the earliest stages of disease.

Read More
3 Reasons to Share Data from Unsuccessful Clinical Trials

3 Reasons to Share Data from Unsuccessful Clinical Trials

  • 0
  • 25 Nov

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.
 

Read More
Highlights from the 2014 Osteoarthritis Imaging Workshop

Highlights from the 2014 Osteoarthritis Imaging Workshop

  • 0
  • 23 Sep

This summer, experts from academia, industry and regulatory sectors gathered in Reykjavik, Iceland for The International Workshop on Osteoarthritis Imaging (IWOAI) to discuss the latest advances related to imaging in Osteoarthritis (OA). Presentations at this conference centered on new imaging techniques and analytical methods for monitoring OA pathophysiology and evaluating imaging data from clinical studies.

Read More

Central Endoscopic Reads in Inflammatory Bowel Disease Clinical Trials: Dr. Harris Ahmad explains the value of an Imaging Core Lab

  • 0
  • 28 Jul

Physicians, pharmaceutical companies and sponsors designing and implementing clinical trials of experimental therapies for inflammatory bowel disease (IBD) face unique challenges, including the use of a video component for assessing mucosal healing and the trend toward centralization of endoscopic evaluations. Furthermore, study design in IBD trials can vary significantly with regard to reader paradigms, approaches for assessing reader variability, and adjudication processes.

Read More

Bone Safety Studies for Diabetes Trials: A Q&A with Dr. Colin Miller

  • 0
  • 17 Jul

Later this month, Colin Miller, PhD, CSci will give a webinar focused on imaging endpoints for fracture risk assessment in clinical trials for diabetes drugs. As a preview to his webinar, I sat down with Colin to discuss the current regulatory landscape surrounding the safety of diabetes drugs and newer approaches that clinicians are using to monitor skeletal integrity.

1. What are some of the types of drugs that are available for treating diabetes?

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

@ArenaIntPharma pls contact our events coordinator via traditional channels
bioclinica (30 minutes ago)
eHealth Solutions president Mukhtar Ahmed speaking at #phorum17 Apr. 27 https://t.co/OaBPodxZBF https://t.co/QjHQR1LbU1
bioclinica (54 minutes ago)
Join @Bioclinica April 28 at NJ Statewide Career & Internship Fair, Rutgers Univ. https://t.co/NH3wsToDTh
bioclinica (1 hour ago)
RT @MySCRS: 96.7% of patients want to know results of #ClinicalTrials yet only 9% are able to find them after study ends. https://t.co/SxtG…
bioclinica (1 hour ago)
RT @SCDM_DataDriven: SCDM is looking for volunteers to revise the Certification Exam! Are you interested? Learn more https://t.co/X7ZYvur2fm
bioclinica (1 hour ago)
RT @ACROhealth: Follow #CTAW2017 next week to learn how more #clinicaltrial participation could help us discover better treatments. https:/…
bioclinica (1 hour ago)

Latest Blogs: